Zentalis medical chief acquires 9,727 shares

The shares were tied to the April–September 2026 employee purchase period and priced at 85% of the April 1, 2026 closing price.

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. Chief Medical Officer Ingmar Bruns acquired 9,727 common shares on September 30, 2026, through the company’s 2020 Employee Stock Purchase Plan. The shares were purchased at $2.18 per share, based on 85% of the closing price on April 1, 2026, for the ESPP purchase period from April 1 through September 30, 2026. Bruns held 43,059 shares directly after the acquisition.

Insider Trade Summary

Grant/Award: 9,727 shares

Grant/Award 1 txn

Insider Bruns Ingmar

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	9,727	$2.18	$21K

Holdings After Transaction: Common Stock — 43,059 shares (Direct)

Footnotes (2)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c).
2. F2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026.

Key Figures

Common shares acquired: 9,727 shares Price per share: $2.18 per share Direct shares after acquisition: 43,059 shares +1 more

4 metrics

Common shares acquired 9,727 shares September 30, 2026, through the 2020 Employee Stock Purchase Plan

Price per share $2.18 per share ESPP acquisition on September 30, 2026

Direct shares after acquisition 43,059 shares Ingmar Bruns’s reported holdings following the September 30, 2026 transaction

ESPP pricing basis 85% Of the closing price on April 1, 2026

Key Terms

2020 Employee Stock Purchase Plan, ESPP purchase period, Rule 16b-3(c)

3 terms

2020 Employee Stock Purchase Plan technical

"pursuant to the Issuer's 2020 Employee Stock Purchase Plan"

ESPP purchase period technical

"for the ESPP purchase period"

Rule 16b-3(c) regulatory

"This transaction is exempt under Rule 16b-3(c)."

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ZNTL shares did Chief Medical Officer Ingmar Bruns acquire, and at what price?

Ingmar Bruns acquired 9,727 Zentalis common shares at $2.18 per share on September 30, 2026, through the company’s 2020 Employee Stock Purchase Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 05:20 PM Accepted by SEC EDGAR 10/01/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bruns Ingmar

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2026		A(1)	V	9,727	A	$2.18(2)	43,059	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c).

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026.

Remarks:

	/s/ James B. Bucher, attorney-in-fact for Ingmar Bruns	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)